The current interest in the clinical use of the hematopoietic CSF. In a considerable number of phase II studies (Table 1) growth factors (HGF) in the treatment of patients with acute and in some randomized studies ( Table 2) experience of the use of HGF in the treatment of AML.
Introduction
The probability of infection and the risk of infectious mortality The rationale of applying hemopoietic growth factors (HGF) correlate directly with the severity and duration of neutroto the treatment of adult patients with acute myeloid leukemia penia. 37 G-CSF and GM-CSF stimulate the survival, prolifer-(AML) is mainly two-fold. First, the introduction of HGF may ation and maturation of myeloid precursor cells in vitro. [38] [39] [40] hasten the hematopoietic regeneration following chemoThese growth factors in addition may activate the function of therapy and thus reduce morbidity and mortality. Second, in granulocytes. GM-CSF for instance has been shown to be a vitro studies have shown that HGF might sensitize AML cells neutrophil activator 41 and it increases chemotactic activity. 42 to chemotherapy and the coadministration of HGF with GM-CSF enhances the superoxide release from human grachemotherapy might enhance the antileukemic efficacy of nulocytes stimulated by chemotactic peptide, 43 and it triggers treatment. At present approximately 60-80% of adults attain the respiratory burst in adherent human neutrophils. 44 Cytoa complete remission on induction chemotherapy and failures kines exert pleiotrophic effects on several lineages of human are mainly caused by infectious complications during neutrohematopoietic cells. GM-CSF activates especially monocytes penia or are due to treatment-resistant leukemia. The inciand macrophages. These cell populations may be of special dence of death during hypoplasia varies between 15 and 25% interest in AML patients suffering from fungal infection and and the incidence of refractory AML varies between 15 and monocytes and macrophages may also have tumoricidal 25% among multicenter studies of adults with AML.
1-7 Among activity. [45] [46] [47] [48] Likewise, G-CSF activates diverse functions of elderly patients with AML the average probability of failure mature neutrophils: chemotactic activity 49 and the production due to infections ranges from 15-35% and primary nonof superoxide, 50 alkaline phosphatase 51 and myeloperoxiresponsiveness to chemotherapy has been estimated at 10-dase. 52 G-CSF is thought to be more restricted to the myeloid 45%. [8] [9] [10] In a large recent study, covering a broad age range, lineage in its actions, although secondary activation by G-CSF hypoplastic death was seen in 5.6% of patients of 40 years or of other hematopoietic cell populations has been described. less and in 23.7% among patients over 60 years. Refractory
Whether a specific effect of a myeloid growth factor is exerted disease was the cause of failure of induction therapy in 15%
by myeloid cells only, will not be considered in this review. of patients younger than 60 years and in 22% of elderly individuals. 11 Future treatment development in patients with AML directly depends on intervention strategies designed to overClinical application of G-CSF and GM-CSF in nonmyeloid come the problems of treatment resistance and the complihematological malignancies cations of cytopenia. This explains the current interest in the use of HGF.
In controlled studies in patients with solid tumors G-CSF has Since 1987, growth factors have been clinically available been applied following the completion of chemotherapy. This for the treatment of AML in an effort to improve outcome. application has been shown to shorten neutropenia by 4 to 5 In these studies granulocyte-macrophage colony-stimulating days and reduce the use of antibiotics. 53, 54 The results of a factor (GM-CSF) and granulocyte colony-stimulating factor (G- controlled study in patients treated for non-Hodgkin's lym-CSF) have mainly been utilized. In recent years, more than phoma showed a reduction in the incidence of neutropenia 1000 patients with AML have been treated with G-CSF or GMas a result of G-CSF treatment but significant reductions in the use of antibiotics or duration of hospitalization were not apparent. However in patients assigned to G-CSF therapy the dose intensity of chemotherapy was increased. 55 A trial in patients with non-Hodgkin's lymphoma using GM-CSF dem- These results are from the TAD-9 treated subset only (n = 25). b Data from the patients with de novo AML, an additional 10 patients with secondary AML were included in the study.
acute lymphoblastic leukemia G-CSF has provided a signifiPhase II studies in AML to enhance hemopoietic recovery after chemotherapy cant reduction in the duration of neutropenia from a median of 12.5 days in controls, to a median of 8 days in patients treated with G-CSF. A trend to fewer infections was apparIn several nonrandomized studies the administration of G-CSF or GM-CSF was started after the completion of chemotherapy ent. 57 G-CSF was administered in a controlled study of patients undergoing autologous transplantation for nonmyeand continued until granulocyte recovery. In one phase II study (Table 1) patients with AML in relapse and elderly loid malignancies. This resulted in a reduction of the time to neutrophil recovery (defined as 0.5 × 10 9 neutrophils/l) from patients with AML were treated with GM-CSF at 250 g/m 2 /day after chemotherapy.
16
Previously treated 20 to 11 days, which was associated with a decrease in the use of intravenous antibiotics. 58 In another prospective study patients from the same center were used as controls. The duration of neutropenia (defined as the recovery of neutrophils in autologous bone marrow transplantation these results were confirmed: a reduction of the duration of neutropenia from 20 to 0.5 × 10 9 /l) in the GM-CSF-treated patients was shortened from 16 to 10 days. The results suggested a greater rate of to 14 days was observed in the G-CSF-treated group and there were fewer days of infection and hospitalization and less anticomplete remissions (50% as compared to 32%) and a lower mortality during induction (14% as compared to 32%) in GMbiotics were used. Survival, however, did not improve. 59 A prospective randomized trial of G-CSF with the object of CSF-treated patients. In a second similar study that used GM-CSF at 120 g/m 2 /day, a reduction of the number of days of enhancing the repopulation abilities of autologous peripheral blood progenitor cells showed a reduction of the time to neuneutropenia was not observed. 14 A beneficial effect of GM-CSF was not noted in this study. In patients treated with GMtrophil recovery (from 16 to 10.5 days), a shorter hospital stay (18 vs 24 days) and less days on nonprophylactic antibiotics CSF and historical controls the CR rates were 50 and 53%, and the mortality rates were 42 and 32%, respectively. In a (11 vs 15 days) for the patient-group treated with G-CSF. 60 In allogeneic marrow transplantation of HLA-matched sibling third uncontrolled study, G-CSF was applied to previously untreated patients and patients with secondary AML. 25 The donors the time of neutrophil regeneration to Ͼ0.5 × 10 9 /l was reduced by 3-4 days in patients receiving GM-CSF as commedian age of the study group was 60 years. The therapeutic regimen consisted of high-dose cytarabine and idarubicin. In pared to controls. 61, 62 Application of GM-CSF resulted in fewer serious infections 61 and a shorter hospital stay. 62 In this study of G-CSF (dose 10 g/kg) the CR rate was 65% and the mortality 13%. In a fourth study G-CSF was applied to addition in a study in allogeneic and autologous bone marrow transplant recipients with graft failure it was observed that elderly patients with untreated AML and the results were compared to those of historical controls. 35 In the group of patients 50% of patients with graft failure had an increase in neutrophils as compared to matched historical controls after treattreated with G-CSF a reduction in the duration of neutropenia from 17 to 13 days was seen. Although the proportion of ment with GM-CSF (250 g/m 2 ). The survival of the patients treated with GM-CSF was suggested to be improved. 63, 64 Thus, patients achieving CR did not significantly differ from those of the controls a reduction of the toxic death rate from 32 to 8% evidently the efficacies of G-CSF and GM-CSF to reduce the duration and severity of neutropenia have been demonstrated in the G-CSF-treated group was suggested (P = 0.04). The latter therapeutic improvement was attributed to the reduction in a variety of clinical settings in patients treated for hematological malignancies. The issue of the optimal dose and timing of the length of neutropenia. Taken together the results of these uncontrolled prospective studies would suggest that the of growth factor administration, has not been settled entirely. There is as yet no consensus on criteria that define conditions introduction of G-CSF or GM-CSF might be of some benefit with regard to accelerated neutrophil reconstitution, reduced and subsets of patients that may be treated with hematopoietic growth factors in a most cost-effective way.
mortality and perhaps a better response rate.
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Table 2
Results of randomized studies of GM-CSF and G-CSF after chemotherapy in AML Randomized studies in AML to enhance hematopoietic the second study a reduction in the frequency of resistance to chemotherapy and an improved remission rate (from 47 to recovery after chemotherapy 70% complete remissions; P = 0.002) were reported. 29 The third study on the use of G-CSF postchemotherapy revealed The results of a limited number of randomized studies that were concerned with evaluating the role of G-CSF or GMidentical CR rates (42 and 49%), although the time of neutropenia was shortened by 3-4 days in G-CSF-treated patients. 34 CSF after the completion of chemotherapy have been reported (Table 2) . Five studies were conducted in previously untreated In the latter two studies elderly patients were treated with similar chemotherapy. The differences in the CR rates in both patients. One study was done in patients with relapsed or refractory AML, and included some patients with acute lymthese studies cannot be readily explained. Three randomized studies on the use of GM-CSF after phoblastic leukemia and with chronic myeloid leukemia in blast crisis 15 (Table 2) . These studies were all done in a relachemotherapy have been reported. In one of these studies yeast derived GM-CSF 17 was used, the other two studies tively older population, as the median ages of the patient groups in each of the trials vary between 43 and 71 years. In applied E. coli-derived GM-CSF. 18, 36 In the first study 17 the leukemic blasts in the marrow at day 10 after the start of three studies GM-CSF was used, in the other three studies G-CSF was evaluated. In all studies the application of G-CSF chemotherapy had to be cleared according to the protocol to permit the initiation of treatment with GM-CSF. The third or GM-CSF after chemotherapy resulted in a reduction of the duration of severe neutropenia, although it varied from 2-12 study 36 had a factorial design including four schedules of incorporating GM-CSF during and after chemotherapy. The days. In the first study in previously treated patients a slightly better response rate was noted in G-CSF treated cases. 15 In results from none of these studies indicated an advantage for 318 A, cytarabine; Ac, aclarubicin; Ams, amsacrine, CHD-ara-C, continuous high-dose cytarabine; D, daunomycine; E, etoposide; F, fludarabin; H, hydroxyurea; HD-Ara-C, high-dose cytarabine; I, idarubicin; M, mitoxantrone; S-HAM, sequential high-dose cytarabine and mitoxantrone; T, 6-thioguanine; CR, complete remission; d, days; mo, months; NR, not reported; hist contr, retrospective comparison with historical controls. P values when reported and р0.05. patients receiving GM-CSF as regards the response to chemoreduction of infection-related morbidity and mortality that would justify application of G-CSF or GM-CSF to all AML therapy or mortality. However, median survival was better in the patient group receiving GM-CSF in one study. 17 Why the patients undergoing intensive chemotherapy has not been observed. improvement of survival following GM-CSF therapy was evident in only one of the various studies reported so far cannot What about a possible effect of G-CSF or GM-CSF therapy on survival? The study by Rowe et al 17 was the only one to be easily explained, although it should be noted that the yeastderived GM-CSF preparation was employed in this particular show an improvement of survival, which has mainly been attributed to a reduction of the incidence of death from infecstudy. It is also noteworthy that a reduced complete remission rate and an increase in the frequency of resistant disease tion. This result has as yet not been reproduced in any other randomized study. Whether the choice of yeast-derived GMamong the patients treated with GM-CSF after chemotherapy was seen in one study. 36 The fact that GM-CSF after chemo-CSF has played a role in the clinical efficacy has not been settled. therapy was not given (n = 3) or prematurely stopped (before day 28, n = 41) for a variety of reasons in more than 80% of Thus, the results of currently available studies do not clearly establish a role for G-CSF or GM-CSF in modifying the the randomized patients, precludes a meaningful interpretation. In the latter study the comparative sizes of the patient response to induction chemotherapy or survival. Does the failure to demonstrate survival benefits of growth factor therapy groups were relatively small.
Beneficial effects of G-CSF or GM-CSF treatment on the rule out a role of these cytokines in AML treatment? 65, 66 As discussed earlier, G-CSF and GM-CSF have been shown to number of severe infections or the need for antibiotic treatment have been reported. In the randomized G-CSF studies be effective for reduction of neutropenia and infections and mortality as a consequence of neutropenia in patients treated fewer documented infections were observed in one study 15 and patients in the G-CSF arm had fewer days with fever and for solid tumors, non-Hodgkin's lymphoma and in patients receiving a bone marrow transplant. This may raise questions on antibiotic treatment in another study. 34 Application of GM-CSF reduced WHO grade 4-5 infections significantly in one as to why a reduction of neutropenia is not effective in improving outcome in patients with AML. An explanation for of the three GM-CSF studies. The reduction of the duration of neutropenia in this study was significant (P = 0.025), however the number of days were not given.
e This is a prospectively randomized phase II trial involving mainly patients with relapsed or refractory disease. f For explanation see Table 2 . The analysis presented here is based on the comparison of the results of treatment groups +/− and +/+ versus groups −/− and −/+. a lack of clinical usefulness could relate to the fact that the stimulatory effects of G-CSF and GM-CSF on AML blast cells in vivo and the possible risk of stimulating leukemic outenhanced recovery of a few days has only a negligible added value in patients with AML. These individuals are often neugrowth or recurrence following in vivo therapy with these growth factors. Receptors for a variety of cytokine receptors, tropenic for comparatively prolonged periods of time from the start of chemotherapy onwards and infections generally including G-CSF, GM-CSF and IL-3, are expressed on AML cells at physiological densities in most patients. [67] [68] [69] These appear during an early phase of granulocytopenia, ie before growth factor intervention shows measurable effects. Thus, the receptors are of high affinity. When the cognate ligands are added to cultures of AML cells, proliferation appears to be lack of efficacy could at least in part be due to the fact that in this particular clinical setting the effects of G-CSF and GMinduced in the great majority of cases. Both G-CSF and GM-CSF may stimulate the uptake of tritiated thymidine of AML CSF are only modest. It is of note that studies on HGF have mainly been conducted in elderly patients, in whom treatment blast cells and colony formation in vitro. [70] [71] [72] [73] The complete remission rate, the number of patients with resistant disease outcome as such is generally quite poor. It is conceivable that the inability of HGF to modify outcome of treatment to a large and remission duration of patients receiving growth factors in the randomized studies were not inferior to those receiving extent is determined by the intrinsic poor risk of the disease in these individuals. There is a lack of studies in newly diagplacebo ( Table 2 ), indicating that stimulation of AML regrowth in vivo as yet has not appeared as a problem with an apprecinosed young and middle-aged adults with AML where outcome may be more easy to modify. able clinical impact.
Stimulation of AML regrowth by G-CSF and GM-CSF in Toxicity of G-CSF and GM-CSF in patients with AML vivo
The observation that functional cytokine receptors are
Only modest toxicity related to G-CSF treatment has been reported. G-CSF in patients with AML infrequently causes expressed on AML cells prompted concern about the direct myalgia and bone pain.
15, 29 In a randomized study of G-CSF Modulation of the AML cell cycle in vivo following G-CSF and GM-CSF priming in 88 patients, no marked side-effects of G-CSF were noted. 29 In another study, one of 48 patients receiving G-CSF was withWhat is known about cell cycle relationships of acute myeloid drawn because of bone pain. 15 leukemia in man? The fraction of AML cells in S-phase (as Administration of GM-CSF may result in some toxicity, measured by the labeling index, LI) is a function of the cell mainly fluid retention, weight gain and decreased serum procycle time (Tc), and the duration of the S-phase (Ts) tein. 16 In two randomized studies of GM-CSF that were hith-(LI = Ts/Tc). Thus, when the cell cycle time is reduced in the erto reported, differences in cardiac or pulmonary events context of a constant LI, the total number of cells recruited between the GM-CSF and placebo-treated groups were not into S-phase per unit of time increases. Information on these observed.
17,18 An increase in the incidence of weight gain and cell cycle parameters may be relevant for understanding cell skin rashes in the patients treated with GM-CSF has been cycle-dependent cytotoxicity of cytarabin. Data from only few reported in the latter two studies. Generally G-CSF and GMin vivo studies are available. In vivo measurements have dem-CSF can safely be administered to patients with AML.
onstrated that the cell-cycle kinetics of AML may vary widely among individual cases. 89, 90 In one study in 40 patients (26 cases of de novo AML, 11 cases of relapsed AML and three cases of blast crisis of CML) the proportion of AML cells in Sphase ranged from 12-50% (median 23%). The duration of SProblem of resistance to chemotherapy and hematopoietic phase and the cell cycle time of the AML cell population growth factors varied from 4-49 h (median 17 h) and from 16-283 h (median 76 h), respectively. 89 In one small study of three patients it was demonstrated that the continuous infusion of AML cells in the bone marrow. 91 These patients do not enter a complete remission on initial In a variety of phase II studies G-CSF or GM-CSF has been therapy or they relapse following a remission of variable duradministered to patients with AML in an effort to augment the ation. In an effort to increase the efficacy of chemotherapy the chemosensitivity (Table 3 ) and the question was asked interaction of hematopoietic growth factors and AML chemowhether indeed the AML blasts were activated following therapy has been investigated. administration of the growth factor. In one study the effect of Cytosine arabinoside (cytarabine) is probably the single G-CSF (10 g/kg/day, for 72 h) was evaluated in newly diagmost effective cytotoxic agent included in induction therapy nosed patients with AML. The median percentages of S-phase of acute myeloid leukemia. Cytarabine is an analogue of 2′-cells increased from 6.0 to 10.7% during the time interval of deoxycytidine. It is metabolized to Ara-CTP, the active form.
72 h. In four of the 15 cases a decrease of the proportion of Ara-CTP is incorporated into DNA. This results in slowing of AML cells in S-phase was noted. An increase in the percentelongation of the nucleotide chain and a defect in ligation of ages of leukemic bone marrow cells with numerical chromonewly synthesized fragments of DNA.
74 Ara-CTP acts as an somal aberrations was observed in all six patients evaluated inhibitor of DNA-polymerase in competition with deoxycitiby fluorescent in situ hybridization, suggesting an expansion dine triphosphate (dCTP). Inhibition of DNA-polymerase is of the mass of leukemic cells. 92 In six studies GM-CSF was thought to reduce DNA repair. 75 As an inhibitor of DNA-syngiven to patients with AML during intervals varying from 18 h thesis, cytarabine is an antimetabolite. Its cytotoxity is Sto 8 days after which a bone marrow sample was taken for phase-dependent and related to the rate of DNA-synthesis. 76, 77 examination of cell cycle changes. In 31 of 39 patients colReasons for treatment failure of patients with AML in response lected from several studies the percentages of S-phase cells to cytarabine may relate to pharmacological resistance of the increased from 0.2 to 17% following treatment with GMleukemia (eg due to a deletion of deoxycytidine kinase 78 ), or CSF. 20, 22, 31, 32, 90, 93 In the largest study (12 patients evaluated) 32 kinetic resistance (cells not in S-phase may escape cell killing). the percentages of AML cells in S-phase increased from an Enhanced cytotoxicity of cytarabine against AML colony-foraverage of 11.1 ± 2.7 to 19.0 ± 3.7 (± s.e.m.) following the use ming cells (AML-CFU) following incubation of the cells with of GM-CSF for 24 h. In one study in five patients the adminis-G-CSF, IL-3 or GM-CSF has been demonstrated by various tration of GM-CSF reduced the AML cell cycle time in two investigators. [79] [80] [81] [82] [83] There is an average three-fold increase of patients by 50% while in two other cases no significant the cytotoxicity of cytarabine to AML clonogenic cells in the change was apparent. In a fifth case the cell cycle time rose context of CSF stimulation for GM-CSF (range 2.2-229-fold) three-fold. 94 These studies thus as a matter of fact provide and IL-3 (range 1.5-63.2-fold), corresponding to an additional proof in support of the principle that treatment of patients with cell kill in the magnitude of 1-1.5 log on the Ara-C dose-AML with HGF may exert evidently measurable biological response curve. 84 Costimulation of the AML cells with these effects on the neoplasm in vivo, although the alterations of cytokines in culture enhances the incorporation of Ara-CTP the cell cycle activity may be heterogeneous among individinto cellular DNA. 84, 85 This has not only been shown for Gual cases. CSF, GM-CSF and IL-3, but also for PIXY321 (a fusion protein of GM-CSF and IL-3) 86 and stem cell factor. 87 Blast cell DNA polymerase-␣ activity is increased by GM-CSF and this
Clinical results of chemotherapy priming with G-CSF and increased activity is related to augmented Ara-C incorporation GM-CSF and cytotoxic AML cell kill. 88 Apparently, the activation of AML cells by hematopoietic growth factors through their cog-
The clinical results of phase II studies testing the concept of nate receptors expressed on these cells may change both the priming are compiled in Table 3 . A concern about the simulmetabolic and the kinetic status of the cells and augment taneous application of chemotherapy and HGF therapy has been that normal hemopoietic precursor cells might also be chemosensitivity in vitro.
84,88
Review W Terpstra and B Löwenberg 321 recruited into the cell cycle and become more susceptible to not been investigated. The choice of the best combination of growth factors is determined by efficacy, side-effects and damage by chemotherapy. Consequently, prolonged cytopenias as an adverse effect of HGF therapy could be anticipated.
costs. It may require a considerable effort to define the usefulness of individual and combinations of growth factors. NeverHowever, no unusually long periods of neutropenia and thrombocytopenia have been observed in patients who theless, a limited number of growth factors are now undergoing phase I and II trials in AML. received G-CSF or GM-CSF for priming (Table 3) . In a phase II trial, 56 newly diagnosed patients treated with chemoIn several phase I and phase II trials interleukin-3 (IL-3) has been examined for the reduction of neutropenia in patients therapy and concurrent GM-CSF were evaluated. 21 A reduced response rate (CR from 68 to 48%; P = 0.011), an increased undergoing chemotherapy or autologous bone marrow transplantation in nonmyeloid malignancies. [96] [97] [98] [99] IL-3 according to probability of resistant disease (from 14 to 32%) and reduced survival (p = 0.052) in patients receiving GM-CSF for priming the results of these studies did not appear more active for promoting neutrophil recovery than GM-CSF, however platelet were noted in comparison to 176 historical controls. The results of two other studies 22, 32 did not indicate an increase recovery was moderately enhanced. AML blasts in most cases express IL-3 receptors on the cell surface. IL-3 may activate in the probability of attaining CR in GM-CSF-treated patients, neither was such an effect noted in a third study of G-CSF. 23 AML proliferation in tritiated thymidine or colony assays in more than 80% of cases. 70, 71, 73 Further, IL-3 may upregulate However, these studies were uncontrolled so that it is not possible to draw definite conclusions as to whether HGF prim-DNA topoisomerase II alpha thereby augmenting cytotoxicity by an additional intracellular mechanism. 100 These findings ing may have expressed a favorable effect on treatment response or survival.
have stimulated interest in IL-3 for recruitment of AML cells into cell cycle. Cortes et al 101 treated 21 patients with relapsed At this moment, results from five randomized studies in previously untreated patients and one study in relapsed or refracor refractory AML in a dose escalating study of IL-3. IL-3 treatment was started 3 days before chemotherapy that consisted tory patients are available. The results are summarized in Table 4 . One of these studies (Heil et al 26 ) was designed to of idarubicin 12 mg/m 2 /day and cytarabine 1.5 g/m 2 /day for 5 days, and it was continued until the end of chemotherapy. evaluate the effects of GM-CSF during consolidation chemotherapy only, ie after patients had been induced into complete
The regimen was considered too toxic to allow further clinical evaluation. Wielenga et al 102 applied escalating doses of IL-3 remission. In another study variable regimens of GM-CSF during and after chemotherapy were evaluated. 36 In most studies to patients with relapsed AML treated with mitoxantrone or daunorubicin and cytarabine (200 mg/m 2 /day, 7 days). IL-3 GM-CSF was given concomitantly with chemotherapy and then continued until neutrophil recovery. An increase in the was given concurrently with the chemotherapy and continued postchemotherapy until neutrophil recovery. Toxicity was efficacy of chemotherapy might translate into an increase of CR rate, a reduced relapse rate or an improved survival probmodest. The complete response rate was 50%. Gore et al 103 used IL-3 with the purpose of augmenting chemotherapy in ability. CR percentages did not improve and the percentages of patients with resistant disease were not reduced in patients 15 high-risk patients with AML, that had achieved remission. IL-3 was started 3 days before chemotherapy and continued treated with a combination of chemotherapy and HGF. However, it should be noted that with the exception of two studies until completion of chemotherapy. No excessive toxicity is mentioned. Interestingly, the application of IL-3 alone (3 days) the number of patients included in the comparative arms of these trials were 40 or less. Data on overall survival are availresulted in the disappearance of CFU-AML that could be grown from the remission bone marrow in four out of six able from four studies and do not show advantages for GM-CSF priming either. A detrimental effect of GM-CSF priming cases studied. PIXY321 is a fusion protein of GM-CSF and IL-3. [104] [105] [106] [107] In on disease-free survival was suggested in a recent update of the study by Bü chner et al 95 for the category of patients over an ongoing study of AML patiens that included six patients in remission PIXY321 was well tolerated but insufficient data are 60 years of age.
Thus, while an increment in the fraction of S-phase AML available on enhancement of neutrophil and platelet recovery. 108 In poor prognosis AML treated with high-dose cytaracells and a faster transit through the cell cycle had been correlated with a more effective kill of AML precursors in vitro, bine and mitoxantrone PIXY321 was used for priming and for the reduction of neutropenia. In this study PIXY321 was priming with GM-CSF in vivo has not (or not yet) been shown to augment the efficacy of chemotherapy. An explanation for relatively well tolerated and 12 of 37 patients attained a complete remission. blasts and a quantitative lack of mature cell stages. When leukemic cells could be induced to terminal differentiation, they might be driven to lose clonogenic potential and extinguish.
In a murine leukemia model the abnormal balance between Other cytokines in the treatment of AML proliferation and maturation may be restored by exposure to cytokines, resulting in induction of maturation and supAs yet, a possible therapeutic role of mainly G-CSF and GM-CSF was investigated in patients with AML. The hypothesis pression of growth of the neoplasm. In the studies of Lotem 112 In 25 cases of a series of 41 specimens of AML exposed to Gthe differentiating effect of ATRA on acute promyelocytic leukemia cells in vitro. It remains to be seen whether G-CSF CSF and all-trans retinoic acid (ATRA) in vitro morphological and immunological signs of maturation were observed. 113 In enhances the therapeutic efficacy of ATRA in the treatment of patients with acute promyelocytic leukemia.
124,125
AMLs with a translocation involving the AML1 gene on chromosome 21 (mainly with the translocation t (8;21) ) the exposure to G-CSF or IL-5 in serum-free suspension culture resulted in morphological maturation towards neutrophils and Future perspectives eosinophils, respectively. 114 In a small clinical study, four newly diagnosed patients with a t(8;21) AML were treated Dose intensification of AML therapy has been shown to result in improved survival, at least in patients younger than 60 with G-CSF for 3-4 weeks before induction chemotherapy was initiated. All patients had a progressive reduction of peryears. Clinical application of hematopoietic growth factors may reduce the associated morbidity and mortality. A ipheral blood blast cell count, which was associated with an increase of mature granulocytes, presumably reflecting matureduction of the duration of neutropenia in patients with AML can be reproducibly achieved following treatment with G-CSF ration of the leukemic clone. A significant reduction in the percentage of marrow leukemic blasts was noted in two or GM-CSF. This reduction has as yet not resulted in significant clinical benefits, ie better response rates or improved surpatients, a partial remission was obtained in one of these two patients. After 20-28 days leukemic regrowth occurred in vival. GM-CSF applied simultaneously with chemotherapy for enhancing cytotoxicity did not reveal favorable effects either. three patients. 115 These results could be consistent with an in vivo differentiating effect of G-CSF similar to the effect Approaches of chemotherapy priming of leukemia employing G-CSF have not been pursued. Whether the cytokine dose observed in vitro.
Administration of G-CSF or GM-CSF in vivo without schedules that have been applied were optimal is questionable. Additional studies would appear warranted to critically additional chemotherapy, has occasionally resulted in clinical remissions. Using restriction fragment length polymorphism evaluate variations of dose, choice of cytokines and combinations of cytokines in distinct subsets of patients with AML. (RFLP) for analysis of bone marrow subpopulations of patients with myelodysplastic syndromes it was shown that the adminDifferentiation therapy of AML as a concept has been validated by the successful treatment of acute promyelocytic leuistration of growth factors may sometimes induce maturation of the abnormal clone.
116,117 Rare cases of patients with AML kemia with ATRA. The differentiation-inducing capacities of growth factors have been demonstrated, in particular in the have been reported, in whom differentiation may have been induced. A patient with a hypoplastic leukemia and sepsis AML subtype with a t(8;21). The question as to whether AML growth factor induced differentiation for therapeutic goals received G-CSF. This resulted in disappearance of the leukemic blasts and in normalization of the platelet counts. 118 In may deserve a broader application is of significant interest. Cells from a significant fraction of cases of AML express ca second patient with hypoplastic acute myeloid leukemia and pancytopenia who received G-CSF for treatment of pneumpl, the receptor for thrombopoietin. 126, 127 Proliferation of AML cells in response to stimulation with thrombopoietin is monia, a complete hematological remission was observed with persisting anemia. 119 A third patient treated with G-CSF frequently seen. The stimulative effect of thrombopoietin is augmented when it is applied in combination with other and high-dose methylprednisone for severe infection and adult respiratory distress syndrome entered a remission that growth factors such as stem cell factor, IL-3, IL-6 or GM-CSF. 128, 129 Thrombopoietin is an important new cytokine, that was maintained until subsequent allogeneic bone marrow transplantation. 120 A fourth patient with minimally differenmay have special clinical relevance for the treatment of thrombocytopenia in patients with AML. tiated leukemia (M0) and pneumonia was treated with GM-CSF which was followed by a complete remission of 9 months
Autologous marrow transplantation offers a treatment modality that is currently used in patients with AML up to 60 duration. At relapse, in the absence of active infection, GM-CSF was reintroduced and a second complete remission of 5 years of age and has been shown to result in long-term remissions in a significant proportion of patients, [130] [131] [132] [133] but it months duration ensued. 121 In one study, G-CSF was given to patients who had relapsed after allogeneic bone marrow is associated with retarded hematopoietic reconstitution posttransplant. The mobilization of autologous peripheral blood transplantation for leukemia or myelodysplasia. Three out of seven patients (one with CML, one with AML and one with progenitor cells (PBPC) might be a vital alternative to the use of autologous marrow grafts in patients with AML. These PBPC refractory anemia with excess of blasts) responded with a complete hematological and cytogenetic remission and the recan be harvested after chemotherapy with the use of several growth factors or combinations of growth factors. Transplanestablishment of donor hematopoiesis. 122 In these incidental cases a mechanism of in vivo terminal differentiation of tation of PBPC after myeloablative therapy may reduce the
